United States, Oct. 23 -- The U.S. Food and Drug Administration today announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration's efforts to accelerate medical innovation and deliver breakthrough treatments. NAIN is designed to advance the science, tools, and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system. NAIN's inaugural initiative, the Alzheimer's Prevention Accelerator, will focus on advancing medical products that help delay or prevent Alzheimer's disease.?Both efforts support the National Alzheimer's Project Act (NAPA), the federal government's comprehensive roadmap for c...